Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 1, 2002, Pages 47-56

  Goerner, Martin ^a   Gooley, Theodore ^a   Flowers, Mary E D ^a   Sullivan, Keith M ^a   Kiem, Hans Peter ^a   Sanders, Jean E ^a   Martin, Paul J ^a   Storb, Rainer ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chronic GVHD

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROCARBAZINE; PSORALEN; RAPAMYCIN; STEROID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ADULT; APLASTIC ANEMIA; ARTICLE; ASEPTIC NECROSIS; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION PREVENTION; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PROGNOSIS; QUALITY OF LIFE; REFRACTORY ANEMIA; SCORING SYSTEM; SIBLING; SKIN MANIFESTATION; SURVIVAL RATE; WHOLE BODY RADIATION; ADOLESCENT; FOLLOW UP; HISTOCOMPATIBILITY TEST; ISOGRAFT; MIDDLE AGED; PRESCHOOL CHILD; STATISTICS; STEM CELL TRANSPLANTATION; SURVIVAL;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANEMIA, REFRACTORY; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, ISOGENEIC;

EID: 0036167770     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm11858190     Document Type: Article

References (44)

1. Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease
2. Scleroderma-like graft-versus-host disease as late consequence of bone-marrow grafting
3. Allogeneic marrow grafting for treatment of aplastic anemia
4. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings
5. Aplastic anemia treated by allogeneic bone marrow transplantation: A report on 49 new cases from Seattle
6. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
7. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
8. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
9. Analysis of late infections in 89 long-term survivors of bone marrow transplantation
10. Immunological recovery after bone marrow transplantation: Role of age, graft-versus-host disease, prednisolone treatment and infections
11. Long-term outcome after marrow transplantation for severe aplastic anemia
12. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
13. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease
14. Thalidomide for the treatment of chronic graft versus host disease
15. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506
16. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus
17. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient
18. Thalidomide for treatment of patients with chronic graft-versus-host disease
19. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): Safety analysis
20. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
21. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors
22. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients
23. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
24. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
25. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation
26. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts
27. Marrow transplantation for treatment of aplastic anemia: An analysis of factors associated with graft rejection
28. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience
29. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: Beneficial effect of a protective environment
30. Marrow transplantation in thirty "untransfused" patients with severe aplastic anemia
31. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis)
32. Cyclophosphamide and anti thymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers
33. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation
34. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
35. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes
36. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical a GITMO/EBMT randomized trial
37. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation
38. How I treat chronic graft-versus-host disease
39. Advances in the treatment of graft-versus-host disease
40. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA)
41. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation
42. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms
43. The importance of confirming graft-versus-host disease (GVHD) diagnosis
44. Development of a prognostic model for grading chronic graft-versus-host disease